International Myeloma Society 6th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2025

International Myeloma Society 6th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2025

 Include: 9 videos + 1 pdf, size: 9.91 GB

Target Audience: hematologists, oncologists treating multiple myeloma

 Information:

The 6th Immune Effector Cell Therapies in Multiple Myeloma Workshop is an advanced two-day educational event dedicated to the latest innovations in immune-based treatments for multiple myeloma. This workshop delivers in-depth scientific updates alongside practical, case-driven discussions to help participants optimize clinical outcomes.

What You Will Learn

• Latest clinical trial data on CAR T-cell therapies targeting BCMA and GPRC5D

• Advances in bispecific antibodies and T-cell engagers, including teclistamab, elranatamab, talquetamab, and others

• Strategies to manage toxicities such as cytokine release syndrome, cytopenias, and organ-specific complications

• Emerging therapies: allogeneic CAR T, CAR-NK cells, dual antigen targeting, and trispecific antibodies

• Approaches to overcome resistance and enhance treatment response through combination regimens and immune modulation

Event Details

• Dates: March 28–29, 2025

• Location: Boston Marriott Long Wharf, Boston, Massachusetts

Who Should Attend
This workshop is ideal for:

• Hematologists and oncologists treating multiple myeloma

• Clinical researchers and trial investigators in immune therapy

• Advanced practice providers and pharmacists involved in immune effector cell therapy care

• Industry professionals and academic experts interested in translating research into clinical practice

Why Attend

• Gain comprehensive insights into the latest immune effector cell therapy developments

• Learn practical management strategies for complex therapy-related toxicities

• Network with global leaders and peers in the myeloma research community

• Apply cutting-edge scientific knowledge directly to patient care

Topics:

• IEC2025Program.pdf
• SESSION 1 CLINICAL UPDATES ON CAR T CELLS.mp4
• SESSION 2 CLINICAL UPDATES ON BISPECIFIC ABS TCE’S.mp4
• SESSION 3 PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPY.mp4
• SESSION 4 NOVEL APPROACHES IN THE CLINIC.mp4
• SESSION 5 MANAGING TOXICITIES OF T CELL ENGAGING THERAPIES.mp4
• SESSION 6 CORRELATES OF RESPONSE AND RESISTANCE.mp4
• SESSION 7 STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPIES.mp4
• SESSION 8 KEY QUESTIONS IN IMMUNE THERAPY.mp4
• WORKSHOP ON SECONDARY MALIGNANCIES AND NON-RELAPSE MORTALITY.mp4